Synapse - Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxis

Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxis Journal Article

Authors:	Piedra, K.; Peterson, T.; Tan, C.; Orozco, J.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Lesokhin, A.; Shah, U.; Lu, S.; Patel, D.; Derkach, A.; Wilkins, C. R.; Korde, N.
Article Title:	Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxis
Abstract:	Incidence of venous thromboembolism (VTE) varies across different regimens in newly diagnosed multiple myeloma (NDMM) patients. Limited data exist on the use of direct oral anticoagulants as thromboprophylaxis in the setting of haematologic malignancies, specifically multiple myeloma. In this retrospective study of 305 NDMM patients, VTE rates in those treated with carfilzomib, lenalidomide, dexamethasone (KRD) + aspirin (ASA), bortezomib, lenalidomide, dexamethasone (RVD) + ASA, and KRD + rivaroxaban were statistically significant, 16·1%, 4·8%, and 4·8%, respectively. The findings confirm a higher incidence of VTE when using KRD induction compared to RVD induction and reveal that the use of low-dose rivaroxaban thromboprophylaxis can mitigate this risk without an observable increase in bleeding rates. © 2021 British Society for Haematology and John Wiley & Sons Ltd.
Keywords:	multiple myeloma; thrombosis; anticoagulation; haematological oncology; myeloma therapy
Journal Title:	British Journal of Haematology
Volume:	196
Issue:	1
ISSN:	0007-1048
Publisher:	John Wiley & Sons
Date Published:	2022-01-01
Start Page:	105
End Page:	109
Language:	English
DOI:	10.1111/bjh.17772
PUBMED:	34396516
PROVIDER:	scopus
PMCID:	PMC9527668
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85112473963&doi=10.1111%2fbjh.17772&partnerID=40&md5=34440e61c3e1c84267d733502dadc4bb
Notes:	Article -- Export Date: 1 February 2022 -- Source: Scopus